HongRi pharmaceutical industry intensively applied for three different types of new drugs

Both rofluorostat and L-malic acid are new drugs of class 3.1 Among them, rofluorostat is a phosphodiesterase-4 (PDE-4) inhibitor, which is a new COPD treatment drug It was developed by necomine, Switzerland It was approved in the European Union in July 2010 and became the first new oral drug approved for chronic obstructive pulmonary disease treatment in the world for more than ten years At present, the daily average cost is 6 US dollars L-malic acid is often combined with compound amino acid injection to improve the utilization of amino acid, especially for patients with postoperative weakness and liver dysfunction Another new drug, fasudil hydrochloride and sodium chloride injection, whose indications are to improve and prevent cerebral vasospasm and cerebral ischemia symptoms after subarachnoid hemorrhage operation, belongs to the compound preparation, which is the change of the main product, fasudil hydrochloride injection The sales volume of the latter in 2013 is nearly 200 million, with a growth rate of 38% At present, the main products of HongRi pharmaceutical industry are mainly concentrated in the field of cardio cerebrovascular, with a single product structure In the past two years, the company has not only been deeply involved in the field of cardio cerebrovascular, but also actively expanded other fields PTS, a new anti-cancer drug, has applied for production approval to the State Administration, and new drugs in other fields, such as flupentine maleate, have also been queuing up in the drug administration.